




**Smarter anesthesia.
Safer recoveries.**

**Senzime AB
Philip Siberg**



A deadly, paralyzing poison


Curare



Paralytic drugs are now standardized to facilitate safe surgery

100 million
patients a year receive
paralytic drugs

Paralyzes
patient in ~45
seconds



87% of patients
are overdosed with
reversal drugs, and 13%
underdosed²

~40% of patients
leave the OR with
residual paralysis¹, at risk of
complications

1. Without monitoring
2. Bowdle et al., 2023

Monitoring during anesthesia for improved patient safety: The TetraGraph neuromuscular monitoring system

Algorithm-powered monitoring to secure precise dosing of paralytic drugs empowering clinicians with real-time signals to confidently determine when it's safe for patients to breathe on their own.

>4,700

TetraGraphs
delivered

>800,000

Patients
monitored

>100

Patents covering
our innovations

>40

Markets in
commercial phase

TETRAGRAPH
Next-Generation



Senzime pioneers a radical technology shift enabling more precise monitoring of patients under anesthesia



>100%
variability¹

1980's

Subjective assessment

Using a peripheral nerve stimulator or only clinical signs to subjectively assess level of block.



51%
variability²

1990's

Legacy monitors

based on AMG/KMG-technology monitor muscle movement, the *indirect effects* of paralytic drugs



0.3%
variability²

2020's

Senzime's TetraGraph

powered by EMG-technology monitors muscle action potentials, the *direct effects* of paralytic drugs.

EMG-based neuromuscular monitoring has shown to increase patient safety and reduce costs

0% complications

related to post-operative residual block, when used with reversal drugs


70% reduction

of the cost of reversal drugs as compared to not using quantitative monitoring.



Thilen S. et al 2024: Anesthesia & Analgesia

Senzime's TetraGraph enables safe, effective, and less costly surgery



Patient is deeply blocked to secure no movement during surgery – accurately monitored by the TetraGraph®

The market we are transforming

15,000
Hospitals



>10,000
hospitals
have NMT
equipment

160,000
Operating Rooms



>80,000 AMG
monitors in the
market

Approx. 6-8,000
EMG monitors in
use, so far

>100 million patients




Estimated that
40-50% of patients
are monitored with
some type of
neuromuscular
technology.

Nine months 2025: Strong growth and clear steps towards profitability


- 1 80% growth in constant currencies
- 2 Sensor deliveries grew 78%
- 3 Underlying Gross Margin strengthened
- 4 OPEX stable at plan
- 5 EBITDA improved by 20%

Jan–Sept 2025 revenues (MSEK)



Our installed base of TetraGraph monitors keeps growing...

Total delivered units of TetraGraph systems




1723 (776)
TetraGraphs
delivered
YTD

TETRAGRAPH
Next-Generation




...driving recurring sales of disposable sensors

Patients monitored with the TetraGraph, accumulated



Supportive guidelines and practice recommendations of quantitative neuromuscular monitoring



Integration and Connectivity to industry leaders



FUKUDA



PHILIPS



 **GE Healthcare**



 **MASIMO**



mindray™



GETINGE 

TetraGraph Xcom and TetraHub – For seamless data integration

Enables connectivity to a wide range of supported external hubs and monitors, ensuring the automatic transmission and display of quantitative TOF monitoring data. The Xcom/TetraHub cable also facilitates integration with compatible EHR connection hubs for streamlined data flow and improved patient care.

Latest additions to integration portfolio

 **SENZIME**

Selected key US TetraGraph installations in 2025

Pacific North-West based hospital system

Contract includes an initial order of 65 next-generation TetraGraph systems for monitoring patients under neuromuscular block for use at multiple hospital locations.

Northern California leading hospital system

Installation of 122 Next-gen TetraGraph monitors.

California University hospital system

Installation of 35 Next-gen TetraGraph monitors.

Win of the world's leading hospital system

Installation of Next-Gen TetraGraph monitors at multiple sites

Texas-based University Hospital

Installation of 65 Next-gen TetraGraph monitors.

Houston Medical Center hospital system

Installation of 122 Next-gen TetraGraph monitors.

Northern MidWest based hospital system

Installation of 80 Next-Gen TetraGraph monitors.

Veterans Affairs Washington DC

Awarded VA tender for deliveries of Next-Gen monitors.

State-wide US university hospital system in the Southeast


Initial order includes 60 TetraGraph Classic monitors, with the potential to monitor more than 15,000 patients per year. Monitors ordered without clinical evaluation.

Contract with US Department of Defense

“We are proud to be selected as the trusted supplier of our neuromuscular monitoring system to **the most prestigious military hospital in the US**. This contract is the result of our relentless commitment to patient safety, our scientific leadership, and our organization’s unique ability to provide long-term support to hospitals”



Walter Reed
National Military
Medical Center




Senzime is an industry leader

TetraGraph utilization of >80%

vs.

Competitor utilization of <8%



These 5 leading accounts ("The 5") have approx. 350 TetraGraph Units. All are running and have upgraded to new Next-Gen TetraGraph. "The 5" consume around 85,000 sensors in average per year, equal to approx. 240 sensors per TetraGraph and year. Average sensor sales of "The 5" is approx. SEK 2.5 million per hospital over last 12 months

the ANESTHESIOLOGY annual meeting

American Society of Anesthesiologists*
San Antonio • October 10-14, 2025 • #ANES25

QI Project for Adherence to ASA Practice Guidelines for NMBA Monitoring and Reversal

A. Deshpande, J. B. Mraovic
1 The Ohio State University College of Medicine
2 The Ohio State University Wexner Medical Center Department of Anesthesiology

INTRODUCTION

- Neuromuscular blocking agents are crucial to safe and effective anesthesia, and effective monitoring for the status of blockade is essential when determining usage of reversal agents.
- Following the 2023 practice guidelines for monitoring and antagonism or neuromuscular blockade, our institution- The Ohio State University Wexner Medical Center- installed quantitative train-of-four (TOF) in all operating rooms.

AIM

- To improve adherence to ASA recommendations regarding neuromuscular blocking agent (NMBA) monitoring and reversal at our institution

METHOD

- Utilized the DMAIC process to frame project goals and plans
- Define (D): lack of adherence to standard monitoring guidelines as outlined by ASA in 2023.
- Measure (M): reviewed all cases when NMBA were used within a 2-week period. Excluded cases without intubation/extubation times (tracheostomy usage/prolonged intubation, etc)
- Analyzed (A) M phase data including usage and documentation of quantitative monitor use and appropriate NMBA reversal agents.

RESULTS

- Inappropriate use of monitoring and reversal in 92.18% of cases
- Lack of reporting/usage of quantitative TOF data (7.8%)
- Large drop off in qualitative data reporting after reversal (85.6%→58.3%)
- Lack of reporting/inconsistencies in data resulting in only 54.8% correctly reported usage of reversal agent
- Overwhelming majority usage of sugammadex as reversal agent (99.5%)

Figure 1: DMAIC process outlining QI Project Creation

CONCLUSIONS

- Currently assessing root-cause analysis to determine next steps for progression of project.
- Improved awareness and communication with multidisciplinary care team members (Certified Registered Nurse Anesthetists, Anesthesiology Assistants) key to improving monitoring documentation
- Following conclusion of root-cause analysis, we will proceed to the improvement phase by testing the agreed upon strategy (education vs charting alert vs automatic charting)

REFERENCES

- Thilen SR, Weigal WA, Todd MM, Dutton RP, Lien CA, Grant SA, Szokol JW, Eriksson LI, Yaster M, Grant MD, Agarwal M, Marbella AM, Blonck JF, Domino KB. 2023 American Society of Anesthesiologists practice guidelines for monitoring and antagonism of neuromuscular blockade: a report by the American Society of Anesthesiologists task Force on Neuromuscular Blockade. *Anesthesiology* 2023;136(1):13-31. doi:10.1097/ALN.0000000000004379.
- Munday LM. Define, measure, analyze, improve, control (DMAIC) methodology as a roadmap in quality improvement. *Qim J Qual Eff Healthc*. 2022;5(2):44-6. doi:10.36401/QJSH-22-X2.

ACKNOWLEDGEMENTS

We would like to thank the department of anesthesia at the Wexner medical center for their continued cooperation for this project, as well as the American Society of Anesthesiologists for their guidance.

CONTACT INFORMATION

Email corresponding PI:
Boris.Mraovic@osumc.edu

N=396	Yes	No
Quantitative TOF before reversal	31 (7.8%)	365 (92.2%)
Quantitative TOF after reversal	1 (0.3%)	395 (99.7%)
Qualitative TOF before reversal	31 (7.8%)	365 (92.2%)
Qualitative TOF after reversal	259 (65.7%)	137 (34.3%)
Sugammadex	341 (85.6%)	55 (13.9%)
Qualitative TOF after reversal	231 (58.3%)	165 (41.7%)
Sugammadex	394 (99.5%)	2 (0.5%)
Neostigmine	2 (0.5%)	394 (99.5%)
Appropriate dose of sugammadex used	184 (54.8%)	152 (45.2%)
Appropriate dose of neostigmine used	0 (0%)	2 (100%)



Supported by Key Opinion Leaders



“Bringing the Next-generation TetraGraph into our community hospital has transformed how we manage neuromuscular block.

It has improved patient safety, standardized our practices, and reduced our annual drug spend by more than \$100,000.”

Dr. Aaron Persinger

Anesthesiologist, Boulder Valley Anesthesiology
Medical Director, UCHealth Broomfield Anesthesiology
Medical Director, Pre-Anesthesia Testing Clinic, UCHealth Broomfield



Backed by a strong investor base



Largest shareholders	Sept 30, 2025	
Crafoord family and the Crafoord Foundation	25,896,551	16,5
Segulah Venture AB, Segulah AB, Segulah Medical Acceleration AB	15,870,271	10,1
Fredrik Rapp	11,879,088	7,6
Fjärde AP-fonden	8,187,000	5,2
Avanza Pension	7,953,362	5,1
Unionen	6,080,000	3,9
Swedbank Robur Microcap	4,779,994	3,0
TIN Ny teknik	4,516,917	2,9
CBNY-National Financial Services	4,336,554	2,8
Nordnet Pensionsförsäkring	3,730,694	2,4
Others	63,984,615	40,7
Total	157 215 046	100%

Crafoordska stiftelsen
GRUNDAD AV HOLGER CRAFOORD 1980



June raise of 110.4 MSEK by issue of 24 million new shares at SEK 4.60 per share, corresponding to market price. **CEO comment:** "The raised capital gives us the prerequisites to realize our current strategic plan and reach positive cash flow."



Leading the paradigm-shift of the decade in Operating Rooms across the world

**Capno-
graphy**



**Depth of
anesthesia**



**EMG-based
Neuromuscular
monitoring**

1980's

1990's

2000's

2010's

2020's

**Pulse Oximetry &
AMG-based NMT**



**Cerebral
Oximetry**



So, join us on our mission to

**Safeguard
every patient's
journey, from
anesthesia to
recovery.**

